GAMMA Investing LLC Acquires 342 Shares of Danaher Co. (NYSE:DHR)

GAMMA Investing LLC increased its holdings in shares of Danaher Co. (NYSE:DHR) by 18.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,219 shares of the conglomerate’s stock after buying an additional 342 shares during the period. GAMMA Investing LLC’s holdings in Danaher were worth $554,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Stokes Family Office LLC acquired a new stake in shares of Danaher during the third quarter worth $511,000. Bison Wealth LLC grew its holdings in Danaher by 43.3% during the third quarter. Bison Wealth LLC now owns 7,864 shares of the conglomerate’s stock valued at $1,951,000 after purchasing an additional 2,377 shares during the period. Interchange Capital Partners LLC increased its stake in Danaher by 15.1% in the third quarter. Interchange Capital Partners LLC now owns 1,372 shares of the conglomerate’s stock valued at $340,000 after purchasing an additional 180 shares in the last quarter. Rathbones Group PLC raised its holdings in Danaher by 23,773.6% in the third quarter. Rathbones Group PLC now owns 229,187 shares of the conglomerate’s stock worth $56,861,000 after purchasing an additional 228,227 shares during the period. Finally, V Square Quantitative Management LLC boosted its position in shares of Danaher by 20.4% during the third quarter. V Square Quantitative Management LLC now owns 7,034 shares of the conglomerate’s stock worth $1,745,000 after purchasing an additional 1,192 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on DHR shares. HSBC raised Danaher from a “hold” rating to a “buy” rating and raised their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Bank of America upped their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Robert W. Baird increased their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. StockNews.com raised Danaher from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Barclays increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Insider Activity at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock worth $37,536,717. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $257.51 on Thursday. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average price is $254.06 and its two-hundred day moving average price is $245.00. The company has a market cap of $190.74 billion, a PE ratio of 43.65, a price-to-earnings-growth ratio of 3.94 and a beta of 0.85. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the business earned $2.36 EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.